Science Capital innovative healthcare 2014 Stratified medicine – from design to delivery



Dr Louise Leong PhD FSB Director of R&D Policy

Birmingham, 11 September 2014

Association of the British Pharmaceutical Industry



- Innovative research-based biopharmaceutical companies, both large and small
- Supply 90% of all medicines used by the NHS
- Researching two-thirds of the medicines pipeline
- The statutory body for negotiating on the PPRS

First, let's take a step back to look at the UK ecosystem ...

These are some of our members....






... including CROs and technology companies






No other industrial sector invests more in R&D









What are relevant UK strengths?



- Science base and talent
- Global pharma presence
- Well funded infrastructure for experimental medicine
- National Health Service, potentially "every patient a research patient"
- Commitments to capacity and capabilities in big data Farr, CPRD, etc
- Strong third sector, e.g. research charities
- Robust ethics and governance
- Public dialogue and engagement
- Enterprise, financial markets
- First launch market (historical)

Are we leveraging our strengths?

Why is stratified medicine a priority?




- > Value for patients
- Enable more efficient R&D, more effective medicines
- Require industry & stakeholders to sustain a strong focus to effect complex system changes
- Require partnership approach, with concerted effort

Stratified medicines are with us:

- Increasing part of candidate development pipeline

- Increasing launches both post-hoc and prospective



What does success look like?




- Patients have timely access to stratified medicine in the NHS
- A framework for flexible and broad value assessment which enables funding and commissioning of stratified medicines
- Insights into stratification of diseases through greater precompetitive efforts with academia, NHS and diagnostic sector
- Facilitative environment in the UK to accelerate R&D of stratified medicine, drawing on bio-resources, well-phenotyped patient cohorts with data matched to 'omics and other biological information
- Underpinned by a strong research culture, data culture, collaborative culture
 Bringing medicines to *life*

ABPI vision, and journey 2009 - 2014


Research-driven recommendations and rationale for a UK stakeholder alliance






How to get there?

Policy areas, 2009





Right medicine, right patient, right time

- Science and Technology
- Regulation
- Electronic health records and data linkages
- Reimbursement
- Economics and new business models
- IP
- Patient & physician engagement /education
- Privacy

http://www.abpi.org.uk/industry-info/future/Pages/personalisedmedicines.aspx



... through a UK stakeholder alliance

abpi

Policy partnerships and brokering connections



Precompetitive academic-industry consortia

Research partnerships

MRC-ABPI COPD consortium

Growing global health burden, highly heterogenous disease

- Cohorts and phenotype underpin the workpackages
- Role of infection
- Tissue injury and repair
- Co-morbidities
- AZ-BI-GSK-MSD-Novartis-Pfizer




Bringing medicines to *life*

Plus

- Diabetes
- Dementia
- And more in development...


MRC-ABPI Rheumatoid Arthritis consortium

- Curing early arthritis
- Immunological toolkit
- 12 companies



An integrated UK strategy

Commitments since the ABPI White Paper and alliance building



Bio-resources for R&D



- Experimental medicine facilities £1bn
- Access to tissues biomarker qualification
- STRATUM standardisation and quality
- UK Biobank 500,000 now open
- + imaging + biomarker panel + genomes
- NIHR Bioresource 75,000 volunteers on register



An experimental medicine model to support a stratified medicine approach – points to consider



http://www.abpi.org.uk/our-work/library/medicaldisease/Pages/experimental-medicine-model.aspx

100K Genome project



- 100,000 genomes: patients with rare inherited disease, common cancers and pathogens from the NHS in England
- Genomics England owned by Department of Health
- Whole Genome Sequencing and link to clinical data in NHS
- Generate health and wealth, aiming for new treatments
- Legacy of infrastructure, human capacity and capability in NHS
- World-leaders in genomic medicine
- £100m funding over the next 5 years
- Pilot in 2014, to complete 10K genomes
 apportation and quality control
- annotation and quality control
- Ethics, privacy and governance framework Bringing medicines to *life*





About the 100K Genome Project

We are a new company set up by the Department of Health to help deliver the 100k Genome Project first announced by the Prime Minister David Cameron in December 2012..

This project will sequence the personal DNA code – known as a genome – of up to 100,000 patients over the next five years. This unrivalled knowledge will help doctors' understanding, leading to better and earlier diagnosis and personalised care. Based on expert scientific advice, we will start by tackling cancer, rare diseases and infectious diseases.

The company will manage contracts for sequencing, data linkage and analysis, and set standards for patient consent.

"The UK will become the first ever country to introduce this technology in its mainstream health system."

Genomics England was announced by Jeremy Hunt, Secretary of State for Health, as part of the NHS 65th birthday celebrations on 5 July 2013.

He said: "The NHS has a long track record as a leader in medical science advances and it must continue to push the boundaries by unlocking the power of DNA data.

"The UK will become the first ever country to introduce this technology in its mainstream health system – leading the global race for better tests, better drugs and above all better, more personalised care to save lives.

"Genomics England will provide the investment and leadership needed to dramatically increase the use of this technology and drive down costs."

Prime Minister, David Cameron



Secretary of State for Health, Rt Hon Jeremy Hunt MP



Contact us

Data linkages will facilitate discovery, development, use of SM **ak**

- Safe data
- Single health service, 60M, very diverse
- Deep history of longitudinal data, cohorts eg Scotland, 1920s
- Enable adaptive licensing, real world data studies, responder precision


ABPI Big data roadmap, Nov 2013

Four-point plan to:

- Increase awareness
- Build capability and capacity
- Create sustainable data ecosystem
- Accelerate high value opportunities

"Data linkages for stratified medicine "

IN PRESS – check our website



Bringing medicines to *life*

http://www.abpi.org.uk/our-work/library/industry/Pages/big-data-road-map.aspx

Catapults – speeding businesses to products ... a case for CDx?



CATAPULT

Inspired by the Fraunhofer institutes ...

- A technology and innovation centre where the very best of businesses, scientists and engineers can work side by side on R&D, transforming ideas into new products and services
- Catapult centres will help businesses, reduce innovating risk, offer concentrated expertise, access to cutting edge equipment and specialist facilities to develop and test ideas in reality
- Flexible model

Bringing medicines to life

Cell Therapy Digital Economy High value manufacture Precision medicine ??

UK competitive position




UK environment has supported stratified medicine advancement and shown international leadership


- Disease science, patient resources and faster translation
- Electronic health records, data linkages and informatics
- Genomic sequencing
- Academic clinician base , translational medicine infrastructure
- Participation in EU Innovative Medicines Initiative
- Strong third sector
- Innovate UK (TSB)

What more can the UK be doing?

Where do things stand?







ABPI White Paper – areas for action

- Science and Technology: through industry -academic
 -NHS collaboration
- Regulation and study design global level but UK can lead in EU
- Electronic health records and data linkages, RWD
- Reimbursement HTA /broader value capture and flexibility
- Economics and new business models
- IP
- Pathology, Adoption in the NHS consistency, commissioning, structures … Baselining project
- Patient & Physician engagement /education
- Privacy

Onwards ...



- Data and governance
- Translational medicine approaches
- Regulation
- Appropriate value assessment which delivers timely access

Implementation and use in health service

Societal engagement



Stratified Medicine Baselining survey – use in the NHS

To take part in survey now, email: john.candeto@concentra.org.uk



The Association of the British Pharmaceutical Industry (ABPI) and the Royal College of Pathologists (RCPath) are conducting a survey designed to gather professional opinion on the opportunities and challenges associated with the adoption of stratified medicine in the NHS.

Please click here to access the survey.

While there are increasing efforts to develop the evidence base for stratified medicine, key issues (and challenges) exist around implementation and take up into routine practice. The primary objective of the survey is to build a baseline understanding in four areas: Awareness, Access, Value, and Challenges.

Your views are extremely important to us. The survey should take no more than 15 minutes to complete and your answers will remain anonymous unless you provide your email address in the introduction section of the survey.

Building an understanding of professional opinion and current practice in terms of biomarker directed strategies in real-world situations will help in overcoming some of the challenges likely to be faced by new drug-diagnostic combinations that are currently in development.

Your participation is greatly appreciated. Stephen Whitehead (ABPI) Ian Cree (RC Path)

... and all will be revealed at:



Stratified Medicine:

Discovery to Patient –Mind the Gap ABPI R&D Conference 20 November 2014



REGISTRATION NOW OPEN

ABPI R&D Conference 2014

Stratified Medicine Discovery to Patient – Mind the Gap

Thursday 20 November

30 Euston Square, London

For more information or to view sponsorship opportunities please Visit the <u>R&D Registration website</u> or contact Ivan Dennie at idennie@abpi.org.uk / 0207 747 1416

Confirmed Speakers

Professor Mark Caulfield | Genomics England Professor Dame Sally Davies | Department of Health Professor John Isaacs | Newcastle University Alastair Kent | Genetic Alliance UK Dr Louise Leong | ABPI Professor Adrian Newland | Barts Health NHS Trust | NICE Ben Osborn | Pfizer Tim Pitfield | Janssen Diagnostics Professor Sir John Savill | Medical Research Council Professor Adrian Towse | Office of Health Economics Dr Neil Weir | UCB Stephen Whitehead | ABPI

A single network for the UK





http://www.uk-pgx-stratmed.co.uk

To join for free, email the network manager Christine McNamee: <u>cjmcn@liv.ac.uk</u>

Wolfson Centre for Personalised Medicine University of Liverpool



Thank you